Intervention not reported
fluoxetine:citalopram · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
fluoxetine:citalopram · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
escitalopram:fluoxetine · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
mirtazapine:fluoxetine · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
fluoxetine:paroxetine · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
fluoxetine:sertraline · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
fluoxetine:venlafaxine · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Depressive symptoms · treatment‐resistant depression in adults
Switching to mianserin (60 mg/d) showed no clear difference in depressive symptoms (HAM‐D) Scale from: 0 to 54 (worse) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).
1 finding from 1 review
Leaving the study early · treatment‐resistant depression in adults
Switching to mianserin (60 mg/d) showed no clear difference in dropouts compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).
1 finding from 1 review
Response (> 50% improvement on 29‐item HAM‐D SIGH‐SAD) · treatment‐resistant depression in adults
Switching to mianserin (60 mg/d) showed no clear difference in response (≥ 50% improvement in HAM‐D score) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).
1 finding from 1 review
Remission (HAM‐D total score ≤ 8) · treatment‐resistant depression in adults
Switching to mianserin (60 mg/d) showed no clear difference in remission (HAM‐D total score ≤ 8) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).
1 finding from 1 review
Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with fluoxetine (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
1 finding from 1 review
Failure to remit at endpoint · patients with depression
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ total drop out rate compared with fluoxetine (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with fluoxetine (moderate certainty).
1 finding from 1 review